MAPT and Alzheimer disease: In AD, pathological hyperphosphorylation of tau is mediated by glycogen synthase kinase 3β (GSK3β), and NUB1 has been shown to inhibit GSK3β-mediated hyperphosphorylation of tau by inducing GSK3β degradation (Figure 2A) [58].